Launch a new category in men's nutrition in your market.
en-MASCULINE is a food supplement for men, built around the gut-hormone axis with the ENBIOSIS Digital Twin and AI engine. en-TEAR runs on the same engine. We appoint one exclusive partner per territory.
- Gold, UK Tech Rocketship Awards 2022
- AI-designed formulation
- Food supplement for men
- 90-day programme
One formulation, built into your daily routine.
Designed to fit into an existing daily routine: a 90-day programme in three 500 g jars.
After 40, men's average testosterone falls year after year.
- average yearly fall in total testosterone, men aged 40 to 70
- 1.6%
- yearly fall in bioavailable testosterone in the same men
- 2–3%
- free DHT in stool compared with blood, in young men
- >70×
Massachusetts Male Aging Study (Feldman et al., 2002); Colldén et al., 2019. A later analysis of the same cohort of American men found levels also falling across the population, independent of age.
The shelf
Almost everything on it is a single familiar ingredient: tribulus, saw palmetto, a men's multivitamin.
The shift
Research is looking at the gut. In animal studies, gut bacteria reactivate androgens in the intestine, and an early study of 31 men linked gut microbial composition to testosterone levels. This is the gut-hormone axis.
The product
en-MASCULINE is built for that shift. A daily food supplement for men: three 500 g jars, 90 days, designed around the gut-hormone axis from the first line of the formula.
Most men's supplements start with an ingredient. en-MASCULINE starts with a target.
The usual way to build a supplement is to take a known ingredient and look for an effect. The ENBIOSIS engine works in reverse. It models what the gut microbiome needs to produce, then designs the food-grade inputs that get it there.
The formula is the output of a model, not a list of familiar ingredients.
01Simulate
A digital twin of the gut microbiome models how microbial communities process food-grade inputs and which metabolites they produce.
02Select
AI picks the precursors predicted to lead to the target metabolites.
03Formulate
The result is one ready-to-use daily product.
The engine behind en-MASCULINE already has clinical results.
We publish as we go. Partners receive study updates as the data comes in.
en-TEAR, the engine's first formulation
In a pilot study, tear production rose 60.7% after 8 weeks (Schirmer test, +6.03 mm), and the improvement held at 16 weeks, after intake had stopped. en-TEAR is now in a placebo-controlled randomised trial with a planned 130 participants (NCT07453212).
Pilot: single-arm, n=20 (NCT07148271). Results not yet peer-reviewed.
The ENBIOSIS algorithm, 12 months on
In the open-label 12-month follow-up of a multicentre randomised trial in irritable bowel syndrome, 62.5% of participants on the ENBIOSIS microbiome-guided diet were responders at 12 months, against 34.5% on low-FODMAP (Gut Microbes, 2026).
Responders: 25 of 40 on the personalised diet, 10 of 29 on low-FODMAP.
A placebo-controlled trial in men, under way
A randomised, triple-masked trial of a microbiome-targeted formulation against placebo is enrolling an estimated 112 men in Türkiye. Primary endpoint: change in fasting morning total testosterone at 12 weeks. Primary completion is expected in March 2027.
Registry: NCT07761546, enrolling by invitation.
placebo-controlled trials running now, each one registered on ClinicalTrials.gov.
One market. One partner.
Exclusive distribution
- You
- Register and sell en-MASCULINE across your territory.
- We
- Finished product, full territory exclusivity.
Agency
- You
- Open doors to pharmacy chains, clinics and retailers.
- We
- Supply and invoice direct, you earn commission.
Premix
- You
- Produce under your own brand.
- We
- Bulk formulation for your lines.
Licensing
- You
- Build the formula into your own products.
- We
- License, active blend, technical transfer.
What you get
Your territory, exclusively
No second partner in your market.
Margin that works
Distributor pricing set for your channel, with volume tiers agreed before launch.
Launch support
Registration dossier, label draft and launch plan for your market.
A complete marketing kit
Imagery, education materials, sales deck.
Direct access to our science team
For your key accounts and medical advisors.
The whole portfolio
en-TEAR, en-CLEAR and en-JOY&FIT through the same relationship.
From first call to first shipment.
- 1
30-minute call
We talk through your market, your channels and our terms.
- 2
Territory reserved
We hold your market and share our pack under NDA.
- 3
Registration
We prepare the dossier; you file it in your market.
- 4
First shipment
Product ships with the marketing kit for launch.
Territories are allocated in the order partners qualify.
Your market is not on the list? Ask. We are opening new territories every quarter.
Open now
Europe, the United Kingdom, the Gulf, Central Asia and North Africa.
Already allocated
Türkiye, direct to consumer.
Start with en-MASCULINE. Grow with the portfolio.
- en-TEARGut-eyeOn sale in Türkiye. Pilot results in, placebo-controlled RCT under way.
- en-CLEARGut-skinComing next. Open for licensing.
- en-JOY&FITGut-metabolicComing next. Open for licensing.
We build nutraceuticals the way pharma builds drugs: target first, clinical trials on the public record.
Founded by Ömer Özkan (CEO), Prof. Özkan Ufuk Nalbantoğlu (CTO) and Aycan Gündoğdu (Chief Science Officer). In operation since 2019, built on microbiome and AI research that predates the company.
- registered clinical studies
- 9
- peer-reviewed papers
- 6
- UK Tech Rocketship Awards 2022
- Gold
- countries using the platform
- 16+
Your market could be next.
Tell us where you sell. We reply within two business days and tell you if your territory is open.
Prefer email? Write to [email protected]